Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256292012> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4256292012 endingPage "52" @default.
- W4256292012 startingPage "52" @default.
- W4256292012 abstract "Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their ability to recognize specifically cancer cells and to activate complement- and cell-mediated cytotoxicity and/or to induce growth arrest or apoptosis. The therapeutic potential of anticancer antibodies is significantly limited due to the ability of cancer cells to block killing by complement. Of the multiple resistance strategies exploited by cancer cells, the expression of membrane complement regulatory proteins (mCRPs), such as CD46 (membrane cofactor protein (MCP)), CD55 (decay-accelerating factor (DAF)), CD35 (complement receptor type-1 (CR1)) and CD59, has received most attention. CD46, CD55 and CD35 block the complement cascade at the C3 activation stage and CD59 prevents assembly of the membrane attack complex of complement (MAC). These proteins protect normal tissues from accidental injury by activated complement, but also confer resistance on cancer cells, thereby limiting the effect of complement-fixing monoclonal antibodies. Expression of mCRPs on malignant cells is highly variable, yet there is clear indication that certain tumors express higher mCRP levels than the normal tissue from which they have evolved. mCRP level of expression and cellular location may also vary during malignant transformation and between differentiated and undifferentiated tumors. Neutralizing anti-mCRP mAbs have been used in vitro to elucidate the significance of mCRP expression to the tumor complement resistance phenotype. In general, CD59 appears to be the most effective mCRP protecting tumor cells from complement-mediated lysis. Nevertheless, it acts additively, and in certain tumors even synergistically, with CD55 and CD46. It is envisaged that treatment of cancer patients with mCRP blocking antibodies targeted specifically to cancer cells in combination with anticancer complement-fixing antibodies will improve the therapeutic efficacy." @default.
- W4256292012 created "2022-05-12" @default.
- W4256292012 date "1996-05-01" @default.
- W4256292012 modified "2023-10-16" @default.
- W4256292012 title "Hot pressing of boron carbide at low temperatures" @default.
- W4256292012 doi "https://doi.org/10.1016/s0026-0657(96)93217-8" @default.
- W4256292012 hasPublicationYear "1996" @default.
- W4256292012 type Work @default.
- W4256292012 citedByCount "0" @default.
- W4256292012 crossrefType "journal-article" @default.
- W4256292012 hasConcept C109316439 @default.
- W4256292012 hasConcept C111684460 @default.
- W4256292012 hasConcept C121608353 @default.
- W4256292012 hasConcept C159654299 @default.
- W4256292012 hasConcept C184404459 @default.
- W4256292012 hasConcept C185592680 @default.
- W4256292012 hasConcept C202751555 @default.
- W4256292012 hasConcept C203014093 @default.
- W4256292012 hasConcept C2777726029 @default.
- W4256292012 hasConcept C40677261 @default.
- W4256292012 hasConcept C502942594 @default.
- W4256292012 hasConcept C542903549 @default.
- W4256292012 hasConcept C54355233 @default.
- W4256292012 hasConcept C55493867 @default.
- W4256292012 hasConcept C86803240 @default.
- W4256292012 hasConcept C92731135 @default.
- W4256292012 hasConcept C95444343 @default.
- W4256292012 hasConcept C96232424 @default.
- W4256292012 hasConceptScore W4256292012C109316439 @default.
- W4256292012 hasConceptScore W4256292012C111684460 @default.
- W4256292012 hasConceptScore W4256292012C121608353 @default.
- W4256292012 hasConceptScore W4256292012C159654299 @default.
- W4256292012 hasConceptScore W4256292012C184404459 @default.
- W4256292012 hasConceptScore W4256292012C185592680 @default.
- W4256292012 hasConceptScore W4256292012C202751555 @default.
- W4256292012 hasConceptScore W4256292012C203014093 @default.
- W4256292012 hasConceptScore W4256292012C2777726029 @default.
- W4256292012 hasConceptScore W4256292012C40677261 @default.
- W4256292012 hasConceptScore W4256292012C502942594 @default.
- W4256292012 hasConceptScore W4256292012C542903549 @default.
- W4256292012 hasConceptScore W4256292012C54355233 @default.
- W4256292012 hasConceptScore W4256292012C55493867 @default.
- W4256292012 hasConceptScore W4256292012C86803240 @default.
- W4256292012 hasConceptScore W4256292012C92731135 @default.
- W4256292012 hasConceptScore W4256292012C95444343 @default.
- W4256292012 hasConceptScore W4256292012C96232424 @default.
- W4256292012 hasIssue "5" @default.
- W4256292012 hasLocation W42562920121 @default.
- W4256292012 hasOpenAccess W4256292012 @default.
- W4256292012 hasPrimaryLocation W42562920121 @default.
- W4256292012 hasRelatedWork W1973489195 @default.
- W4256292012 hasRelatedWork W2008361687 @default.
- W4256292012 hasRelatedWork W2016865478 @default.
- W4256292012 hasRelatedWork W2059519404 @default.
- W4256292012 hasRelatedWork W2067077431 @default.
- W4256292012 hasRelatedWork W2084450932 @default.
- W4256292012 hasRelatedWork W2120844308 @default.
- W4256292012 hasRelatedWork W2122854061 @default.
- W4256292012 hasRelatedWork W2443772760 @default.
- W4256292012 hasRelatedWork W2939977586 @default.
- W4256292012 hasVolume "51" @default.
- W4256292012 isParatext "false" @default.
- W4256292012 isRetracted "false" @default.
- W4256292012 workType "article" @default.